Evidence map›Paper›PMID 34893548›Full record

ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience2022

Genetic Reduction of Mitochondria Complex I Subunits is Protective against Cisplatin-Induced Neurotoxicity in

Christopher M Groen, Jewel L Podratz, Joe Pathoulas, Nathan Staff, Anthony J Windebank

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Cognitive Impairment in Multiple Sclerosis.Bioengineering (Basel, Switzerland) · 2023
    Review
  9. eLife · 2023
    Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Cellular Pathogenesis of Chemotherapy-Induced Peripheral Neuropathy: Insights FromFrontiers in pain research (Lausanne, Switzerland) · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Christopher M GroenDepartment of Neurology, Mayo Clinic, Rochester, Minnesota 55905.
Jewel L PodratzDepartment of Neurology, Mayo Clinic, Rochester, Minnesota 55905.
Joe PathoulasDepartment of Neurology, Mayo Clinic, Rochester, Minnesota 55905.
Nathan StaffDepartment of Neurology, Mayo Clinic, Rochester, Minnesota 55905.
Anthony J WindebankDepartment of Neurology, Mayo Clinic, Rochester, Minnesota 55905 Windebank.Anthony@mayo.edu.
Mayo Clinic · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) is a prevalent side effect of widely used platinum-based anticancer agents. There are few predictable risk factors with which to identify susceptible patients. Effective preventive measures or treatments are not available. Here, we have used a model of CIPN in

Indexed as

AnimalsAntineoplastic AgentsCisplatinDrosophila melanogasterDrosophila ProteinsElectron Transport Complex INeurotoxicity SyndromesPeripheral Nervous System DiseasesAntineoplastic AgentsCisplatinDrosophila ProteinsElectron Transport Complex IND-13A protein, DrosophilaCIPNcisplatincomplex IDrosophilamitochondria

Identifiers

PMID34893548
PMCPMC8808726
OpenAlexW4200305444

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.